Browse CEBPB

Summary
SymbolCEBPB
NameCCAAT/enhancer binding protein (C/EBP), beta
Aliases NFIL6; IL6DBP; C/EBP-beta; liver-enriched transcriptional activator protein; nuclear factor of interleukin 6 ......
Chromosomal Location20q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Note=Translocates to the nucleus when phosphorylated at Ser-288. In T-cells when sumoylated drawn to pericentric heterochromatin thereby allowing proliferation (By similarity).
Domain PF07716 Basic region leucine zipper
Function

Important transcription factor regulating the expression of genes involved in immune and inflammatory responses (PubMed:1741402, PubMed:9374525, PubMed:12048245, PubMed:18647749). Plays also a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis. The consensus recognition site is 5'-T[TG]NNGNAA[TG]-3'. Its functional capacity is governed by protein interactions and post-translational protein modifications. During early embryogenesis, plays essential and redundant functions with CEBPA. Has a promitotic effect on many cell types such as hepatocytes and adipocytes but has an antiproliferative effect on T-cells by repressing MYC expression, facilitating differentiation along the T-helper 2 lineage. Binds to regulatory regions of several acute-phase and cytokines genes and plays a role in the regulation of acute-phase reaction and inflammation. Plays also a role in intracellular bacteria killing (By similarity). During adipogenesis, is rapidly expressed and, after activation by phosphorylation, induces CEBPA and PPARG, which turn on the series of adipocyte genes that give rise to the adipocyte phenotype. The delayed transactivation of the CEBPA and PPARG genes by CEBPB appears necessary to allow mitotic clonal expansion and thereby progression of terminal differentiation (PubMed:20829347). Essential for female reproduction because of a critical role in ovarian follicle development (By similarity). Restricts osteoclastogenesis: together with NFE2L1; represses expression of DSPP during odontoblast differentiation (By similarity). ; FUNCTION: Isoform 2: Essential for gene expression induction in activated macrophages. Plays a major role in immune responses such as CD4(+) T-cell response, granuloma formation and endotoxin shock. Not essential for intracellular bacteria killing. ; FUNCTION: Isoform 3: Acts as a dominant negative through heterodimerization with isoform 2 (PubMed:11741938). Promotes osteoblast differentiation and osteoclastogenesis (By similarity).

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001503 ossification
GO:0001541 ovarian follicle development
GO:0001649 osteoblast differentiation
GO:0001701 in utero embryonic development
GO:0001819 positive regulation of cytokine production
GO:0001889 liver development
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0002237 response to molecule of bacterial origin
GO:0002432 granuloma formation
GO:0002521 leukocyte differentiation
GO:0002526 acute inflammatory response
GO:0002544 chronic inflammatory response
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0006953 acute-phase response
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007548 sex differentiation
GO:0007611 learning or memory
GO:0007613 memory
GO:0008406 gonad development
GO:0008585 female gonad development
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022602 ovulation cycle process
GO:0022612 gland morphogenesis
GO:0030099 myeloid cell differentiation
GO:0030278 regulation of ossification
GO:0030316 osteoclast differentiation
GO:0030879 mammary gland development
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0032496 response to lipopolysaccharide
GO:0032633 interleukin-4 production
GO:0032635 interleukin-6 production
GO:0032673 regulation of interleukin-4 production
GO:0032675 regulation of interleukin-6 production
GO:0032753 positive regulation of interleukin-4 production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032945 negative regulation of mononuclear cell proliferation
GO:0033598 mammary gland epithelial cell proliferation
GO:0034976 response to endoplasmic reticulum stress
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0035711 T-helper 1 cell activation
GO:0036003 positive regulation of transcription from RNA polymerase II promoter in response to stress
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042098 T cell proliferation
GO:0042107 cytokine metabolic process
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0042130 negative regulation of T cell proliferation
GO:0042226 interleukin-6 biosynthetic process
GO:0042698 ovulation cycle
GO:0042742 defense response to bacterium
GO:0043200 response to amino acid
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress
GO:0043620 regulation of DNA-templated transcription in response to stress
GO:0044708 single-organism behavior
GO:0045137 development of primary sexual characteristics
GO:0045165 cell fate commitment
GO:0045408 regulation of interleukin-6 biosynthetic process
GO:0045444 fat cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0045600 positive regulation of fat cell differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045667 regulation of osteoblast differentiation
GO:0045669 positive regulation of osteoblast differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045778 positive regulation of ossification
GO:0046545 development of primary female sexual characteristics
GO:0046631 alpha-beta T cell activation
GO:0046651 lymphocyte proliferation
GO:0046660 female sex differentiation
GO:0048511 rhythmic process
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048732 gland development
GO:0050670 regulation of lymphocyte proliferation
GO:0050672 negative regulation of lymphocyte proliferation
GO:0050673 epithelial cell proliferation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050873 brown fat cell differentiation
GO:0050890 cognition
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051402 neuron apoptotic process
GO:0060644 mammary gland epithelial cell differentiation
GO:0060850 regulation of transcription involved in cell fate commitment
GO:0061008 hepaticobiliary system development
GO:0061180 mammary gland epithelium development
GO:0061458 reproductive system development
GO:0070059 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070555 response to interleukin-1
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070664 negative regulation of leukocyte proliferation
GO:0070997 neuron death
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071229 cellular response to acid chemical
GO:0071230 cellular response to amino acid stimulus
GO:0071347 cellular response to interleukin-1
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071593 lymphocyte aggregation
GO:0072574 hepatocyte proliferation
GO:0072575 epithelial cell proliferation involved in liver morphogenesis
GO:0072576 liver morphogenesis
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097421 liver regeneration
GO:0098542 defense response to other organism
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1902105 regulation of leukocyte differentiation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903706 regulation of hemopoiesis
GO:1990440 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0008134 transcription factor binding
GO:0035035 histone acetyltransferase binding
GO:0035257 nuclear hormone receptor binding
GO:0035258 steroid hormone receptor binding
GO:0035259 glucocorticoid receptor binding
GO:0042826 histone deacetylase binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0046982 protein heterodimerization activity
GO:0051427 hormone receptor binding
Cellular Component GO:0000775 chromosome, centromeric region
GO:0000779 condensed chromosome, centromeric region
GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0000793 condensed chromosome
GO:0005667 transcription factor complex
GO:0016363 nuclear matrix
GO:0034399 nuclear periphery
GO:0036488 CHOP-C/EBP complex
GO:0044454 nuclear chromosome part
GO:0044798 nuclear transcription factor complex
GO:0090575 RNA polymerase II transcription factor complex
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG hsa04668 TNF signaling pathway
Reactome R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-1266738: Developmental Biology
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
Summary
SymbolCEBPB
NameCCAAT/enhancer binding protein (C/EBP), beta
Aliases NFIL6; IL6DBP; C/EBP-beta; liver-enriched transcriptional activator protein; nuclear factor of interleukin 6 ......
Chromosomal Location20q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CEBPB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CEBPB and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25238096lung carcinoma; melanoma; colon carcinomaInhibit immunity (T cell function)Transcription factors CCAAT/enhancer binding protein b (C/EBPb) and phosphorylated signal transducer of activator of transcription 3 (phospho-STAT3) centrally regulate MDSC function and expansion
Summary
SymbolCEBPB
NameCCAAT/enhancer binding protein (C/EBP), beta
Aliases NFIL6; IL6DBP; C/EBP-beta; liver-enriched transcriptional activator protein; nuclear factor of interleukin 6 ......
Chromosomal Location20q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CEBPB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCEBPB
NameCCAAT/enhancer binding protein (C/EBP), beta
Aliases NFIL6; IL6DBP; C/EBP-beta; liver-enriched transcriptional activator protein; nuclear factor of interleukin 6 ......
Chromosomal Location20q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CEBPB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2350.612
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6080.821
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0360.986
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6740.187
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9260.69
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3540.907
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3710.423
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3990.792
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3640.83
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1950.863
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0160.993
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2940.0199
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CEBPB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCEBPB
NameCCAAT/enhancer binding protein (C/EBP), beta
Aliases NFIL6; IL6DBP; C/EBP-beta; liver-enriched transcriptional activator protein; nuclear factor of interleukin 6 ......
Chromosomal Location20q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CEBPB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCEBPB
NameCCAAT/enhancer binding protein (C/EBP), beta
Aliases NFIL6; IL6DBP; C/EBP-beta; liver-enriched transcriptional activator protein; nuclear factor of interleukin 6 ......
Chromosomal Location20q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CEBPB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CEBPB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCEBPB
NameCCAAT/enhancer binding protein (C/EBP), beta
Aliases NFIL6; IL6DBP; C/EBP-beta; liver-enriched transcriptional activator protein; nuclear factor of interleukin 6 ......
Chromosomal Location20q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CEBPB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCEBPB
NameCCAAT/enhancer binding protein (C/EBP), beta
Aliases NFIL6; IL6DBP; C/EBP-beta; liver-enriched transcriptional activator protein; nuclear factor of interleukin 6 ......
Chromosomal Location20q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CEBPB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCEBPB
NameCCAAT/enhancer binding protein (C/EBP), beta
Aliases NFIL6; IL6DBP; C/EBP-beta; liver-enriched transcriptional activator protein; nuclear factor of interleukin 6 ......
Chromosomal Location20q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CEBPB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCEBPB
NameCCAAT/enhancer binding protein (C/EBP), beta
Aliases NFIL6; IL6DBP; C/EBP-beta; liver-enriched transcriptional activator protein; nuclear factor of interleukin 6 ......
Chromosomal Location20q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CEBPB collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CEBPB.
ID Name Drug Type Targets #Targets
DB04216QuercetinSmall MoleculeACTB, AHR, ATP5A1, ATP5B, ATP5C1, CBR1, CEBPB, CSNK2A1, CSNK2B, CY ......27